Adipotide
Also known as · FTPP
to clear
How a single dose clears, assuming first-order elimination. The half-life is the biggest driver of how often you dose — start a cycle to see your own cumulative concentration curve.
An experimental fat-targeting peptide that shrank fat mass in primate studies; raised kidney-toxicity concerns. No human safety data.
Targets a prohibitin receptor on fat-tissue blood vessels, triggering apoptosis and reducing the vasculature that feeds fat.
Preclinical only; not for human use.
Reconstituted: refrigerated; protect from light.
This page summarizes publicly available information. None of it constitutes medical advice, prescription, or recommendation to acquire, possess, or use any compound. Many peptides described are research chemicals not approved for human use in the EU. Consult a licensed physician.
Semaglutide
A long-acting GLP-1 receptor agonist for type-2 diabetes and weight management. Slows gastric emptying and suppresses appetite.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with superior weight loss and glycemic control versus semaglutide in head-to-head trials.
Retatrutide
An investigational triple agonist (GIP/GLP-1/glucagon) showing the largest weight-loss figures yet in trials. Not yet approved.